miRNA-221 is elevated in cystic fibrosis airway epithelial cells and regulates expression of ATF6. by Oglesby, Irene K et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Medicine Articles Department of Medicine
1-1-2015
miRNA-221 is elevated in cystic fibrosis airway
epithelial cells and regulates expression of ATF6.
Irene K. Oglesby
Royal College of Surgeons in Ireland
Raman Agrawal
University of Heidelberg
Marcus A. Mall
University of Heidelberg
Noel G. McElvaney
Royal College of Surgeons in Ireland
Catherine M. Greene
Royal College of Surgeons in Ireland, cmgreene@rcsi.ie
This Article is brought to you for free and open access by the Department
of Medicine at e-publications@RCSI. It has been accepted for inclusion in
Medicine Articles by an authorized administrator of e-publications@RCSI.
For more information, please contact epubs@rcsi.ie.
Citation
Oglesby IK, Agrawal R, Mall MA, McElvaney NG, Greene CM. miRNA-221 is elevated in cystic fibrosis airway epithelial cells and
regulates expression of ATF6. Molecular and Cellular Pediatrics 2015, 2:1
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/medart/42
RESEARCH Open Access
miRNA-221 is elevated in cystic fibrosis airway
epithelial cells and regulates expression of ATF6
Irene K Oglesby1, Raman Agrawal2, Marcus A Mall2,3, Noel G McElvaney1 and Catherine M Greene1*
Abstract
Background: MicroRNA (miRNA) and messenger RNA (mRNA) expression differs in cystic fibrosis (CF) versus non-CF
bronchial epithelium. Here, the role of miRNA in basal regulation of the transcription factor ATF6 was investigated
in bronchial epithelial cells in vitro and in vivo.
Methods: Using in silico analysis, miRNAs predicted to target the 3′untranslated region (3′UTR) of the human ATF6
mRNA were identified.
Results: Three of these miRNAs, miR-145, miR-221 and miR-494, were upregulated in F508del-CFTR homozygous
CFBE41o- versus non-CF 16HBE14o- bronchial epithelial cells and also in F508del-CFTR homozygous or heterozygous
CF (n = 8) versus non-CF (n = 9) bronchial brushings. ATF6 was experimentally validated as a molecular target of these
miRNAs through the use of a luciferase reporter vector containing the full-length 3′UTR of ATF6. Expression of ATF6
was observed to be decreased in CF both in vivo and in vitro. miR-221 was also predicted to regulate murine
ATF6, and its expression was significantly increased in native airway tissues of 6-week-old βENaC-overexpressing
transgenic mice with CF-like lung disease versus wild-type littermates.
Conclusions: These results implicate miR-145, miR-221 and miR-494 in the regulation of ATF6 in CF bronchial
epithelium, with miR-221 demonstrating structural and functional conservation between humans and mice. The altered
miRNA expression evident in CF bronchial epithelial cells can affect expression of transcriptional regulators such as ATF6.
Keywords: ATF6; Cystic fibrosis; miRNA-221
Background
Cystic fibrosis (CF) is a common autosomal recessive inher-
ited disease. People with CF (PWCF) have a lower than nor-
mal average life expectancy [1]. Affected individuals typically
become symptomatic in infancy and childhood and classic-
ally present with mucosal infections, exocrine pancreatic in-
sufficiency and elevated sweat chloride levels. Although it is
a multisystem disorder, recurrent lung infections are respon-
sible for the major morbidity and mortality in PWCF.
CF occurs due to mutations in the gene encoding the
CF transmembrane regulator (CFTR) protein, a cyclic
AMP-activated chloride channel that controls the se-
cretion of chloride and bicarbonate ions across the air-
ways and other epithelial surfaces. Six classes of CFTR
mutations have been described, with the class II F508del-
CFTR mutation representing the most common CFTR
mutation worldwide [2]. The misfolded F508del-CFTR
protein encoded by this mutation accumulates in the
endoplasmic reticulum (ER) and fails to reach the apical
surface of epithelial cells to function as an anion channel.
The βENaC-transgenic mouse phenocopies increased airway
Na+ absorption and airway surface liquid depletion character-
istic of human CF airways and develops spontaneous CF-like
lung disease with mucus plugging, chronic airway inflamma-
tion and reduced clearance of bacterial pathogens [3,4].
The ER is the site of protein translation, folding and
processing for transport to secretory vesicles. Perturbation
of the ER can lead to a phenomenon termed ER stress
which results in the initiation of signalling networks aimed
at restoration of ER equilibrium. One ER stress network is
the unfolded protein response (UPR). Activating transcrip-
tion factor 6 (ATF6) is an ER resident transcription factor
and a key component of the UPR [5]. Its activation leads
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to transcriptional induction of ATF6-regulated genes
which function primarily to restore correct protein folding
in the ER.
Recent evidence implicates microRNAs (miRNAs) in
regulation of the UPR [6-9]. miRNAs are short regula-
tory RNAs that hybridise to miRNA recognition ele-
ments (MREs) located largely in the 3′UTR of mRNA
transcripts, leading to mRNA degradation and/or inhib-
ition of translation. Dysregulation of miRNA expression
has been described in numerous disease states including
CF, where the miRNA expression profile of bronchial
epithelial cells has been shown to be altered [10].
To date, there have been no studies examining whether al-
tered miRNA expression regulates expression of UPR genes
in CF airway epithelium. Therefore, we undertook a study to
examine miRNA expression and regulation of ATF6 in CF
and non-CF airway epithelial cells in vitro and in vivo, and
complemented these human studies by analysing the expres-
sion of key miRNAs in a mouse model of CF lung disease.
Methods
Study populations, bronchial brush sampling and miRNA
profiling
Following informed consent under a protocol approved by
the Beaumont Hospital ethics review board, bronchial brush-
ings were sampled and RNA isolated as previously described
[10] from 17 individuals: CF (n= 8, 27.2 + 2.7 years, M/F
5:3), confirmed by sweat testing and/or genotyping, (Table 1)
and non-CF controls (n= 9, 50.8 + 5.4 years, M/F 5:4)
(Table 2). All animal studies were approved by the Animal
Care and Use Committee of the Regierungspräsidium
Karlsruhe, Germany.
Cell lines and culture conditions
Human bronchial epithelial 16HBE14o- and F508del
homozygous CFBE41o- cell lines were obtained as a gift
from D. Gruenert (California Pacific Medical Centre
Research Institute, San Francisco, CA, USA). HEK293
(human embryonic kidney cell line) were obtained from
the European Collection of Cell Cultures (Salisbury,
Wiltshire, UK). Cells were routinely grown in minimum
essential media (MEM+GlutaMax, Gibco, Life Tech-
nologies, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum (Gibco) and 1% penicillin-streptomycin
(Gibco) in 75-cm2 flasks and maintained in a 37°C hu-
midified incubator containing 5% CO2. For experiments,
cells were sub-cultured once 60% to 80% confluency was
achieved and seeded at optimised densities.
In silico analysis. Bioinformatic analysis was performed
using the miRNA target prediction database TargetScan
6.2 to search for putative targets of miRNA differentially
expressed in CF airway epithelium. Subsequently, a range
of databases (including miRWALK http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/micrornapredictedtar-
get.html which incorporates MicroRNA.org, PITA, miRDB
and Microcosm) were interrogated to search for miRNA
targeting human and murine ATF6.
Measurement of human miRNA expression levels by
qRT-PCR
Total RNA was extracted using TriReagent (Sigma-Aldrich,
St. Louis, MO, USA). Generation of cDNA for miRNAs of
interest was performed using Taqman MicroRNA Reverse
Transcription kits (Applied Biosystems, Foster City, CA,
USA). miRNA expression in brushings and cell lines was
measured on a Roche LC480 Lightcycler (Roche, Penzberg,
Bavaria, Germany). Expression of miRNAs relative to miR-
218 was determined using the 2(−ΔΔCt) method. miR-218 was
chosen for normalisation due to a high degree of similarity in
expression levels between CF and non-CF brushings ob-
served in the expression profiling screen. All quantitative
real-time polymerase chain reaction (qRT-PCR) experiments
in cell lines were performed in triplicate, a minimum of three
times and included no-template controls.
Mouse studies
The βENaC-transgenic mouse was originally generated
on a mixed genetic background (C3H/He × C57BL/6)
Table 1 CF patient demographics
CF Sex Age CFTR genotype FEV1 BMI PI Ps. Sa. Asp.
1 M 21 ΔF508/R506T > K 17% 30.5 Y + + −
2 M 29 ΔF508/ΔF508 64% 20.24 Y + − −
3 F 25 ΔF508/R177H 5T 89% 23.15 N - + =
4 M 18 ΔF508/ΔF508 87% 20.89 Y + + +
5 M 23 ΔF508/unknown 27% 17.76 Y + - -
6 F 19 ΔF508/ΔF508 54% 21.71 Y + - -
7 F 25 ΔF508/1717GA 51% 19.62 Y + - +
8 M 31 ΔF508/621 + 1G→ T 83% 22.77 Y + - +
FEV1, forced expiratory volume in 1 s percent predicted; BMI, body mass index;
PI, pancreatic insufficiency (Y, yes; N, no); Ps., colonisation with Pseudomonas
aeruginosa; Sa., colonisation with Staphylococcus aureus; Asp., colonisation with
Aspergillus species.
Table 2 Non-CF control patient demographics
Non-CF Sex Age
1 M 47
2 M 57
3 F 68
4 F 73
5 F 60
6 M 54
7 F 20
8 M 47
9 M 46
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and was backcrossed to the C57BL/6 background as pre-
viously described [11]. Experimental animals were
housed in a specific pathogen-free animal facility of the
University of Heidelberg and had free access to chow
and water. Transgene-positive mice were identified by
PCR of genomic DNA [3], and wild-type (WT) litter-
mates served as controls. The trachea and main stem
bronchi were collected from 6-week-old mice as previ-
ously described [12], and total RNA was isolated using
TRIzol reagents (Invitrogen, Life Technologies, Carlsbad,
CA, USA). Quantitative real-time PCR for miRNAs was
performed with TaqMan assays (Applied Biosystems,
Foster City, CA, USA) as per the manufacturer's
protocols.
Luciferase reporter plasmid transfection
HEK293 cells (1 × 105 in triplicate) were transiently co-
transfected for 24 h with a WT-ATF6 3′UTR (OriGene,
Rockville, MD, USA) firefly luciferase reporter vector
containing the full-length 3′UTR (250 ng), a constitutive
Renilla luciferase vector (100 ng) and 30 nM synthetic
premiR mimics (PM) for miR-145, miR-221 and miR-
494 (Applied Biosystems, Foster City, CA, USA) as indi-
cated or with a scrambled control. PremiR-223, a
miRNA increased in the CF lung but not predicted to
target ATF6, was included as a control. Transfections
were performed using Genejuice (Novagen, Madison,
WI, USA) for plasmid DNA and Ribojuice (Novagen,
Madison, WI, USA) for miRNA in OptiMEM reduced
serum media (Life Technologies, Carlsbad, CA, USA) as
per the recommended conditions. Lysates were prepared
and measurement of luciferase was performed using the
luciferase assay system (Promega, Madison, WI, USA).
Relative luciferase activity was calculated. Endogenous
red fluorescent protein (RFP) expressed by the ATF6
3′UTR reporter was used to monitor transfection
efficiency.
Measurement of mRNA expression levels by qRT-PCR
Total RNA was extracted using TriReagent. For mRNA
gene expression, equal quantities of RNA were reverse
transcribed into cDNA using the Quantitect Reverse
Transcription Kit (Qiagen, Valencia, CA, USA) following
the manufacturer's protocol. Expression of ATF6 mRNA
relative to β-actin (data presented as fold differences)
was determined using the 2(−ΔΔCt) method (details on
primers are shown in Table 3).
Statistical analysis
All analyses were performed using GraphPad PRISM 4.0
(GraphPad Software Inc., San Diego, CA, USA). Results
are expressed as the mean ± SEM and were compared by
Student's t test. Differences were considered significant
at p ≤ 0.05.
Results
ATF6 is predicted to be regulated by miRNAs that are
upregulated in CF airway epithelium
We previously reported differential expression of 68
miRNAs in CF versus non-CF bronchial brushings by in
situ qRT-PCR [10]. In silico analysis of potential targets
of these differentially expressed miRNAs was performed.
ATF6, a protein of interest to us, was predicted to be
regulated by three of the upregulated miRNAs - miR-
145, miR-221 and miR-494 (Figure 1). Figure 1A depicts
the full-length human ATF6 3′UTR with predicted bind-
ing locations for miR-145, miR-221 and miR-494, and
Figure 1B shows the locations and base pair matches of
their proposed binding sites, adapted from TargetScan
6.2. A range of other target prediction databases were
interrogated, and ATF6 was listed as a putative target
of two or more of these miRNAs in six of the eight
databases interrogated, Figure 1C, each with only one
miRNA recognition element predicted in the ATF6
3′UTR.
miR-221 is increased in CF versus non-CF cell lines and
bronchial brushings
Figure 2A shows that miR-221, which was significantly
elevated with a median fold change of 1.92 in CF versus
non-CF bronchial brushings as shown by miRNA profil-
ing [10], is similarly increased in CF versus non-CF cell
lines (p < 0.05) and also in CF versus non-CF bronchial
brushings (p < 0.01).
We have previously reported that miR-145 and miR-
494 are increased in vitro and in vivo in CF versus non-
CF bronchial epithelium [13]. Figure 2B shows the levels
of these miRNAs, normalised to miR-218, in the samples
studied here.
Expression of miR-145, miR-221 and miR-494 is increased
in airway tissues from βENaC-transgenic versus wild-type
mice
miR-145, miR-221 and miR-494 are conserved in mam-
mals. The levels of these three miRNAs were measured
in native airway tissues (trachea and main stem bronchi)
from βENaC-transgenic C57BL/6 mice (βENaC-Tg) and
wild-type littermates and normalised to SNO142.
Figure 3A shows the relative expression of each miRNA
Table 3 Primers used in this study
Gene Primers (5′-3′) Bases spanned Product
size (bp)
hATF6a F-TGAACTTCGAGGATGGGTTC 1,560 to 1,739 180
R-TCACTCCCTGAGTTCCTGCT
hβ-actin F-GGACTTCGAGCAAGAGATGG 747 to 884 138
R-AGGAAGGAAGGCTGGAAGAG
ah, human.
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in the trachea and bronchi of 6-week-old wild-type and
βENaC-Tg C57BL/6 mice. In contrast to human bron-
chial brushings, only miR-221 was significantly increased
in the airway tissues of the βENaC-Tg mice. Figure 3B
depicts the full-length murine ATF6 3′UTR. Compared
to the human ATF6 3′UTR which is 408 bp, the murine
version is significantly longer at 5,422 bp. It contains
two predicted binding locations for miR-221, but none
for miR-145 or miR-494.
miR-145, miR-221 and miR-494 target human ATF6 via re-
pression of an ATF6 3′UTR luciferase reporter
In order to determine whether human ATF6 is regu-
lated by miR-145, miR-221 and miR-494, HEK293 cells
were transiently transfected with a luciferase reporter
vector containing the full-length wild-type 408 bp hu-
man ATF6 3′UTR and a reference Renilla luciferase re-
porter plasmid pRLSV40. Co-transfection with premiR
(PM)-145, PM-221 or PM-494, either alone or com-
bined, resulted in a significant decrease in luciferase
gene expression from the reporter vector containing
the ATF6 3′UTR compared to a scrambled control
(Figure 4; p < 0.05). A premiR for miR-223, a miRNA
not predicted to target ATF6, did not decrease lucifer-
ase activity.
Expression of ATF6 is decreased in CF versus non-CF cell
lines and bronchial brushings
Finally, ATF6 mRNA expression was measured in the CF
versus non-CF cell lines CFBE41o- and 16HBE14o- and in
a selection of CF and non-CF bronchial brushings. Figure 5
shows that expression of ATF6 mRNA, relative to β-actin
mRNA, is significantly decreased in CF, both in vitro (p <
0.01) and in vivo (p < 0.05). There was no difference in
ATF6 expression in homozygous versus heterozygous
F508del CFTR individuals (n = 3 and n = 5, respectively).
Discussion
ATF6 is an ER resident transcription factor involved in
the unfolded protein response. Given the relatively recent
discovery of miRNAs and their potential involvement in
the regulation of almost all cellular processes, we exam-
ined whether miRNAs that are differentially expressed in
CF airway epithelium control expression of ATF6. Here,
we report decreased expression of ATF6 mRNA in
F508del CF bronchial epithelium both in vitro and in vivo
and correlate this observation with increased expression
of miR-145, miR-221 and miR-494, three miRNAs pre-
dicted to target the ATF6 3′UTR. Of these three miRNAs,
only miR-221 is predicted to regulate murine ATF6
mRNA, and in βENaC-Tg mice, expression of miR-221 is
MicroRNA DIANAmT miRanda miRDB miRWalk RNAhybrid PITA MicroRNA.org TargetScan Total
hsa-miR-145 - + - - + - - + 3
hsa-miR-221 + + - + + - + + 6
hsa-miR-494 + + + + + - + + 7
C
+ = predicted to target ATF6; - = not predicted to target ATF6
A
B
Figure 1 miR-145, miR-221 and miR-494 are predicted to target human ATF6. (A) Predicted binding location of miR-145, miR-221 and
miR-494 in the full-length (408 bp) human ATF6 3′UTR and (B) proposed base pair matches for miR-145, miR-221 and miR-494 within the 3′UTR
of ATF6 as predicted by TargetScan 6.2. (C) Predicted targeting of the human ATF6 3′UTR by miR-145, miR-221 and miR-494 by DIANAmt,
miRanda, miRDB, miRWALK, RNAhybrid, PITA, MicroRNA.org and Targetscan 6.2.
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increased in native airway tissues (tracheal and bron-
chial tissues) compared to wild-type mice. Together,
the data implicate altered miRNA expression, in par-
ticular miR-221, in controlling ATF6 levels in CF bron-
chial epithelium.
Based on a number of recent reports, evidence of a
role for miRNA in controlling the UPR is beginning to
emerge. For example, in alpha-1 antitrypsin deficiency,
miR-199a-5p has been shown to control the expression
of many key factors involved in UPR, including ATF6
[6]. In mice, miR-702 also regulates ATF6; however, the
possible existence of miR-702 in the human genome is
low [7]. Other miRNAs implicated in control of the UPR
include miR-122 and miR-30c-3p [8,9]. To date, there
are no reports on miRNA-mediated influences on UPR
components within the CF airway epithelium.
In this study, we observed that levels of miR-145, miR-
221 and miR-494 are increased in CF bronchial epithelial
cells in vitro and in vivo. Previously, we reported how al-
tered levels of miR-145 and miR-494, together with
other factors, can control decreased CFTR mRNA and
protein expression in vivo and in vitro [13]. Here, we ex-
tend our understanding of miR-145 and miR-494 in the
context of CF bronchial epithelial cells by demonstrating
their reciprocal relationship with ATF6 mRNA levels and
provide evidence that miR-221 also contributes to the
post-transcriptional regulation of ATF6. Regarding the ex-
pression of other miRNAs with a proven role in regulating
ATF6 [6,7], neither was detected in CF and non-CF sam-
ples by in situ qRT-PCR arrays [10].
The βENaC-Tg mouse represents a murine model with
CF-like lung disease that mimics an imbalance of CFTR-
mediated anion secretion and ENaC-mediated Na+
absorption characteristic of human CF airways. This im-
balance causes airway surface dehydration and a spontan-
eous lung disease phenotype that shares key features with
human CF including mucus plugging, chronic airway in-
flammation and reduced clearance of bacteria [3,4]. Al-
though the three miRNAs under investigation here are
conserved between humans and mice, only miR-221 was
found to be similarly increased in the trachea and bronchi
of 6-week-old βENaC-Tg versus wild-type mice. Interest-
ingly, bioinformatic analysis of the murine ATF6 3′UTR
revealed two predicted miRNA recognition elements for
miR-221, whereas miR-145 and miR-494 were not identi-
fied as potential regulators. Thus, βENaC-Tg mice may
represent a useful model for further studies into the biol-
ogy and function of miR-221 in CF lung disease. Regard-
ing the age of the mice, 6-week-old mice are comparable
to young adults as previously published for the βENaC-
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Figure 2 Relative expression levels of miR-221 in CF versus non-CF bronchial epithelial cell lines and bronchial brushings. (A) Relative
expression of miR-221 was determined by qRT-PCR using individual TaqMan human miRNA assays and normalised to miR-218 in the CF
bronchial epithelial cell line CFBE41o- compared with its non-CF counterpart 16HBE14o- (three separate cultures measured in triplicate) and
in bronchial brushings (CF, n = 8; non-CF, n = 9). Data are represented as mean ± SEM and were compared by t test (*p < 0.05, **p < 0.01).
All qRT-PCR experiments for cell lines were performed in triplicate and included no-template controls. (B) Relative expression of miR-145
and miR-494 normalised to β-actin in the CF versus non-CF cell lines and bronchial brushings used in (A).
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overexpressing mouse and other models of experimental
lung disease in mice [14,15], and thus similar to the age of
the CF patients studied here. Whether miRNA expression
patterns differ in paediatric versus adult CF patients has
not been studied to date.
More than 95% of the misfolded protein encoded by
the F508del-CFTR mutation is retained in the ER and
subsequently degraded by the proteasome [16]; conse-
quently, less CFTR reaches the apical membrane and
ion transport is impaired. Conflicting opinions exist as
to whether the aberrant folding of F508del-CFTR elicits
an ER stress response and consequently activates the
UPR. A number of studies suggest this is the case
[17,18], whilst others propose that ER stress arises as a dir-
ect result of inherent inflammatory factors and chronic
infection [19-21]. Therefore, it remains controversial
whether mutant CFTR itself causes ER stress, UPR induc-
tion and subsequent inflammation or whether the chronic
inflammation observed in CF is the primary ER stress ef-
fector leading to UPR activation independent of the aber-
rantly folded CFTR. A number of studies have reported a
lack of UPR activation in F508del-CFTR homozygous pri-
mary tracheal cell cultures [22] and nasal epithelial CF15
cell lines [23] under basal conditions. Consistent with this,
increased ER density and Ca2+ signals observed in short-
term primary cultures of F508del-CFTR homozygous CF
cells which disappear over time (30 to 40 days) can be
reproduced in normal bronchial epithelial cells stimulated
with supernatant from CF lung mucopurulent material.
This suggests that airway infection and inflammation and
Figure 3 miR-221 is increased in trachea and bronchi and is predicted to target murine ATF6 3? UTR. (A) Relative expression of murine
miR-145, miR-221 and miR-494 was determined by qRT-PCR using individual TaqMan murine miRNA assays and normalised to sno412 in the
trachea and bronchi of 6-week-old wild-type (n = 9) and βENaC-Tg (n = 6) C57BL/6 mice. Data are represented as mean ± SEM and were
compared by t test (*p < 0.01). All qRT-PCR experiments were performed in duplicate and included no-template controls. (B) Predicted
binding locations of miR-221 in the full-length 5,422 bp murine ATF6 3′UTR and proposed base pair matches as predicted by TargetScan 6.2.
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not the presence of mutant CFTR instigate an ER stress
response [20,21]. Our data supports these studies. We ob-
served lower levels of ATF6 mRNA in CF versus non-CF
cells under basal conditions.
There are a number of limitations associated with this
study. For example, although inhibition of luciferase ac-
tivity in a vector containing the full-length human ATF6
3′UTR indicated that each of the three miRNAs were
capable of decreasing luciferase expression, in order to
demonstrate that miR-145, miR-221 and miR-494 dir-
ectly target the human ATF6 3′UTR, additional experi-
ments using reporter constructs in which the predicted
MREs for the individual miRNAs are deleted or mutated
would be required. Unfortunately, this was not possible
at this time. Also, whilst it would be ideal to demon-
strate decreased ATF6 protein levels in vivo, bronchial
brushings are clinical samples obtained from a highly in-
vasive procedure that yields relatively few cells. The pri-
ority in this study was to assess miRNA and mRNA
expression levels in these rare samples, thus precluding
their use for Western blot analysis. Finally, miRNA and
ATF6 mRNA expressions were examined under basal ra-
ther than agonist-induced ER stress conditions. This ap-
proach was taken in order to establish the behaviour and
relationship of these factors in the context of CF epithe-
lial cells; future work should investigate how infection or
inflammation may impact on the fundamental processes
described here.
Conclusion
Taken together, the data here demonstrate a role for
miR-145, miR-221 and miR-494 in regulating ATF6. The
observation that miR-221 is increased in CF versus non-
CF bronchial brushings and also in native airway tissues
of βENaC-Tg versus wild-type mice indicates that this
miRNA is both structurally and functionally conserved
between humans and mice. Various miRNA-targeting
therapeutics are under investigation for cystic fibrosis,
and it has been demonstrated in proof-of-concept stud-
ies that it is feasible to deliver miRNA modulators into
primary and transformed CF nasal and bronchial epithe-
lial cells in culture [24-26]. In the future, manipulation
of miR-221 levels in vivo using miRNA overexpression
strategies could be used to decrease levels of ATF6 in
CF, thereby limiting ER stress-mediated inflammation.
This strategy may have therapeutic potential for CF or
other conditions where the UPR plays a role.
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Figure 4 miR-145, miR-221 and miR-494 target human ATF6.
Relative luciferase activity in HEK293 cells (1 × 105 in triplicate)
transiently co-transfected with full-length 408 bp human ATF6 3′UTR
firefly luciferase reporter plasmid, a constitutive Renilla luciferase reporter
plasmid (pRLSV40) and scrambled control (Scr), premiR (PM)-223 control,
PM-145, PM-221 and PM-494. Firefly luciferase activity was normalised to
Renilla luciferase activity. Transfection efficiency was monitored by
visualisation of endogenous RFP expressed from the ATF6 3′UTR reporter
plasmid where uniform transfection (estimated to be approximately
50%) was observed across all wells. Data are represented as mean ± SEM
and were compared by t test (*p < 0.05). Data is representative of
three experiments.
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Figure 5 Relative expression of ATF6 in CF versus non-CF
bronchial epithelial cell lines and bronchial brushings. Relative
expression of ATF6 mRNA was determined by qRT-PCR and normalised
to β-actin in the CF bronchial epithelial cell line CFBE41o- compared
with its non-CF counterpart 16HBE14o- (three separate cultures tested
in triplicate) and in bronchial brushings (CF, n = 8; non-CF, n = 9).
Data are represented as mean ± SEM and were compared by t test
(*p < 0.05, **p < 0.01). All qRT-PCR experiments for cell lines were
performed in triplicate and included no-template controls.
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